Core Viewpoint - The article provides an overview of the financing events in the primary market, highlighting the increase in both the number of financing events and the total financing amount compared to the previous week, indicating a growing interest in investment opportunities across various sectors [4][12]. Financing Overview - As of May 23, 2025, there were 130 financing events reported, an increase of 42 events from the previous week, with a total financing amount of approximately 3.828 billion RMB, up by 749 million RMB [4]. - Among these events, 19 had financing amounts of 100 million RMB or more, which is an increase of 3 events from the previous week [4]. - There were 33 public exit cases this week, remaining stable compared to last week [4]. Financing Amount Distribution - A total of 80 financing events disclosed their amounts, with the distribution as follows: - 8 events under 5 million RMB (up by 4) - 39 events between 5 million and 10 million RMB (up by 10) - 11 events between 10 million and 50 million RMB (down by 2) - 19 events between 50 million and 100 million RMB (up by 7) - 3 events between 100 million and 500 million RMB (down by 2) - No events above 500 million RMB [5]. Notable Investment Events - **Satellite Operations**: Penghu Wuyu completed nearly 100 million RMB in Series A financing, led by Wuxi Liangxi Kechuang Industry Mother Fund and Wuxi Liangxi Aerospace Investment Fund, to expand its global operations in satellite IoT [7]. - **Organoids**: Chuangxin International raised nearly 100 million RMB in Series B financing, led by Yueke Fund and Donghai Investment, to accelerate the development of organoid technology [7]. - **Resource Recovery**: Zhongwu Industry Operations secured 500 million RMB in Series A financing to enhance its procurement network and improve supply chain efficiency [8]. - **AI Chips**: Blue Core Computing raised over 100 million RMB in equity financing, with participation from multiple investment institutions, focusing on high-performance chip design [8]. Industry Distribution - The financing events spanned 14 industries, with the top five being: - Healthcare: 28 events - Electronics: 25 events - Information Technology: 19 events - Equipment Manufacturing: 14 events - Consumer Goods and Services: 14 events - These five industries accounted for 76.15% of all financing events [12]. Financing Amount by Industry - The top five industries by financing amount were: - Healthcare: 32.07 million RMB (83.76% of total) - Information Technology: Significant contributions from Whale and other major events - Consumer Goods and Services - Electronics - Equipment Manufacturing - The healthcare sector led with a high number of large financing events [14]. Regional Distribution - The top five regions for financing events were: - Jiangsu: 29 events - Guangdong: 22 events - Zhejiang: 22 events - Beijing: 16 events - Shanghai: 9 events - These regions accounted for 75.38% of all financing events [17]. - In terms of financing amount, Zhejiang led with 829.59 million RMB, influenced by significant events [17]. Financing Rounds - The most active financing rounds were Angel and Series A, totaling 74 events, with Series B ranking third at 23 events [22]. - Series A financing accounted for 37.16% of the total financing amount, followed by strategic financing at 16.09% [22]. Investment Institutions - A total of 129 investment institutions participated in financing activities, with notable activity from Beijing Guoguan and Shenzhen Capital Group [25]. Exit Situation - There were 33 public exit cases, with the healthcare sector leading in the number of exits, followed by materials and electronics [30][31].

Core Insights - Chuangxin International has completed nearly 100 million RMB in Series B financing, led by Yueke Fund and Zhongshan Haochuang Fund, to accelerate the development and global commercialization of organoid technology [2] - The company focuses on precision medicine, new drug development, and intelligent manufacturing, aiming to overcome key industry bottlenecks and promote the intelligent, standardized, and industrialized development of the organoid industry [2][3] - The FDA's new regulation set to be released in April 2025 will phase out animal testing models, recommending human cell models, including organoids, marking a shift towards more realistic human models in life sciences research [2] Company Overview - Chuangxin International Biotech (Guangzhou) Co., Ltd. was established in March 2018 and has built a comprehensive ecosystem covering the entire lifecycle of organoid technology [2] - The company is positioned as a global leader in organoid technology, redefining core pathways in life sciences research through technological innovation and ecosystem reconstruction [3] - The CEO, Dr. Huang Min, stated that the company will leverage this financing round to enhance its technology platform, data intelligence, and industrial applications, aiming to create a product matrix in key areas such as organoid intelligent devices and data systems [3]

创芯国际董事长兼CEO黄敏表示，感谢粤科基金、投控东海及各投资方的高度认可和战略支持。创芯国 际将以此轮融资为契机，以'技术平台+数据智能+产业应用'三维驱动，构建覆盖类器官全生命周期的技 术生态体系，继续加大核心技术研发、产品创新，在类器官智能设备与芯片、数据智能系统等关键赛道 形成产品矩阵，推动技术突破与产业化升级，致力于成为类器官产业全球领航者。 采写：南都·湾财社记者 徐劲聪 据悉，创芯国际是一家类器官领域全产业链创新企业，依托自主创新的核心技术体系，率先构建了覆盖 类器官全生命周期技术一体化生态平台。公司聚焦精准医疗、新药研发与智能智造三大战略方向，围绕 类器官肿瘤治疗、再生医学、合成生物学三大领域的规模化应用，推动类器官行业向智能化、标准化、 产业化方向发展。 作为联合领投方，广东国资投资机构粤科基金方面表示，创芯国际拥有领先的类器官技术和产业化平 台，其技术成果在精准医疗、新药研发等前沿领域应用价值巨大，符合粤科基金聚焦科技核心赛道的投 资理念，相信创芯国际将在行业变革中占据关键位置。 深投控旗下专注早中期科创企业投资的投控东海表示，认可创芯国际的技术深度与成长潜力。本次投资 不仅是投控东海在生 ...